Industries > Pharma > Translational Regenerative Medicine: Market Prospects 2016-2026

Translational Regenerative Medicine: Market Prospects 2016-2026

Can Promising Therapies in Stem Cells, Tissue Engineering and Gene Therapy Change the Way We Treat Rare and Chronic Diseases?

PUBLISHED: 29 January 2016
PAGES: 285
PRODUCT CODE: PHA0087
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0087 Categories: ,

What can be expected from the Translational Regenerative Medicine market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.
 
Our 285-page report provides 170 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole of translational regenerative medicine market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2026? Our study forecasts revenues in the following Translational regenerative medicine submarkets:
• Stem Cell Therapies
• Tissue Engineering
• Gene Therapies

Translational Regenerative Medicine: Market Prospects 2016-2026

See revenue forecasts for some the leading products in the market
How will leading drug perform to 2026? Our study forecasts revenues for a number of leading products in the translational regenerative medicine market including:
• Osteocel Plus
• Trinity ELITE
• TEMCELL /Prochymal
• Apligraf
• Dermagraft
• ReCell
• Neovasculgen
• Glybera (alipogene tiparvovec)
• IMLYGIC (talimogene laherparepvec)

See revenue forecasts for the leading regional markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including:
• US
• Europe
• Asia-Pacific
• Rest of World

Leading companies and potential for market growth
Overall revenue for the Translational Regenerative Medicine market will reach $12.1bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2026.

Our work analyses the key companies in the market. See Visiongain’s analysis of 16 leading companies, including these:
• Alphatec Spine
• Anterogen
• Athersys
• Avita Medical
• AxoGen
• Medipost
• Mesoblast
• NuVasive
• Ocata Therapeutics
• Organogenesis
• Osiris Therapeutics
• Pharmicell
• Regenersys
• TiGenix
• UniQure
• Vericel Corporation

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Historic revenue, analysis and discussion of company performance over the past 5 years
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect translational regenerative medicine industry?
Our new report discusses issues and events affecting the translational regenerative medicine market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of key therapeutic indications
• Changing regulatory landscape challenging new entrants and major market players alike
• Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Translational Regenerative Medicine: Market Prospects 2016-2026 report helps you
In summary, our 285-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Translational Regenerative Medicine market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for each major submarket – discover prospects for leading translational regenerative medicine products in the following areas: stem cell therapies, tissue engineering and gene therapy.
• Revenue forecasts to 2026 for 9 of the leading products in the Translational Regenerative Medicine market – discover prospects for leading translational regenerative medicine products including: Osteocel Plus, Trinity ELITE, TEMCELL /Prochymal, Apligraf, Dermagraft, ReCell, Neovasculgen, Glybera (alipogene tiparvovec) and IMLYGIC (talimogene laherparepvec)
• Revenue forecasts to 2026 for one leading national market and two leading regional markets – US, Europe, Asia-Pacific and Rest of World
• Assessment of 16 leading companies – analysis of products, revenue, mergers & acquisitions, sales by region, therapeutic area and product type
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the translational regenerative medicine market and leading companies. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Translational Regenerative Medicine: Market Prospects 2016-2026


Download sample pages

Complete the form below to download your free sample pages for Translational Regenerative Medicine: Market Prospects 2016-2026


Latest Pharma news

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

READ

Categories